罗氏制药(RHHBY.US)今日宣布，其旗下创新药罗可适®(Ocrevus®，通用名：奥瑞利珠单抗注射液/ocrelizumab injection)正式获得中国国家 ...

此次奥瑞利珠单抗在中国获批主要依据OPERA I、OPERA II和ORATORIO等多个全球III期临床研究的积极结果。 2025年3月31日，罗氏制药今日宣布，其旗下创新药 ...

（原标题：罗氏制药(RHHBY.US)罗可适®在华获批用于治疗复发型和原发进展型多发性硬化症） 智通财经APP获悉，罗氏制药(RHHBY.US)今日宣布，其旗下 ...

3月31日，罗氏制药宣布，其旗下创新药罗可适®（Ocrevus®，通用名：奥瑞利珠单抗注射液/ocrelizumab injection）正式获得中国国家 ...

The FDA approved ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo; Genentech), a twice-yearly subcutaneous injection, for relapsing multiple sclerosis (RMS) and primary progressive multiple ...

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis (RMS/PPMS). “Twice-yearly SC injection of OCR, administered in ...

LONDON, July 14: In a groundbreaking development, thousands of people suffering from multiple sclerosis (MS) in England are set to benefit from a new 10-minute injection that drastically reduces the ...

Ocrelizumab can help halt the symptoms of two forms of MS. The under-the-skin injection has recently been approved by medicines regulators in Great Britain and Europe. MS affects more than 150,000 ...

Ocrelizumab comes as a solution which has to be injected intravenously or directly into the vein. • The injection has to be inspected for the presence of any visible particles or cloudy ...